ATE463567T1 - Transgene mäuse zur studierung von neurodegenerativen syndromen - Google Patents

Transgene mäuse zur studierung von neurodegenerativen syndromen

Info

Publication number
ATE463567T1
ATE463567T1 AT00951857T AT00951857T ATE463567T1 AT E463567 T1 ATE463567 T1 AT E463567T1 AT 00951857 T AT00951857 T AT 00951857T AT 00951857 T AT00951857 T AT 00951857T AT E463567 T1 ATE463567 T1 AT E463567T1
Authority
AT
Austria
Prior art keywords
transgenic
human
animal
antibody
human transgenic
Prior art date
Application number
AT00951857T
Other languages
English (en)
Inventor
Antonino Cattaneo
Simona Capsoni
Francesca Ruberti
Original Assignee
S I S S A Scuola Internaz Supe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1999MI001783 external-priority patent/IT1313607B1/it
Priority claimed from IT2000RM000306 external-priority patent/IT1317039B1/it
Application filed by S I S S A Scuola Internaz Supe filed Critical S I S S A Scuola Internaz Supe
Application granted granted Critical
Publication of ATE463567T1 publication Critical patent/ATE463567T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00951857T 1999-08-06 2000-07-28 Transgene mäuse zur studierung von neurodegenerativen syndromen ATE463567T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999MI001783 IT1313607B1 (it) 1999-08-06 1999-08-06 Animali transgenici non umani anti-ngf
IT2000RM000306 IT1317039B1 (it) 2000-06-05 2000-06-05 Animali transgenici non umani esprimenti anticorpi anti-ngf.
PCT/IT2000/000321 WO2001010203A2 (en) 1999-08-06 2000-07-28 Non-human transgenic animals for the study of neurodegenerative syndromes

Publications (1)

Publication Number Publication Date
ATE463567T1 true ATE463567T1 (de) 2010-04-15

Family

ID=26331673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00951857T ATE463567T1 (de) 1999-08-06 2000-07-28 Transgene mäuse zur studierung von neurodegenerativen syndromen

Country Status (9)

Country Link
US (1) US7273964B1 (de)
EP (1) EP1255824B1 (de)
JP (1) JP2003518922A (de)
AT (1) ATE463567T1 (de)
AU (1) AU783964B2 (de)
CA (1) CA2388341A1 (de)
DE (1) DE60044149D1 (de)
DK (1) DK1255824T3 (de)
WO (1) WO2001010203A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044293A2 (en) * 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20040212A1 (it) * 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (de) 2020-05-26 2024-11-13 TrueBinding, Inc. Verfahren zur behandlung von entzündungskrankheiten durch galectin-3-blockierung
CN116135015B (zh) * 2023-03-29 2025-04-18 中国科学院昆明动物研究所 一种提升树鼩行为实验内在驱动力的试验方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008483A1 (en) * 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DE69828574T2 (de) 1997-11-14 2005-10-06 Sankyo Co., Ltd. Transgenes Tier als Modell für Allergie und seine Verwendung
WO1999029860A1 (en) * 1997-12-08 1999-06-17 Ontogeny, Inc. Cadherin-like polypeptides, methods and compositions related thereto

Also Published As

Publication number Publication date
DK1255824T3 (da) 2010-07-19
EP1255824B1 (de) 2010-04-07
US7273964B1 (en) 2007-09-25
DE60044149D1 (de) 2010-05-20
CA2388341A1 (en) 2001-02-15
WO2001010203A3 (en) 2002-09-12
WO2001010203A2 (en) 2001-02-15
AU783964B2 (en) 2006-01-05
AU6470000A (en) 2001-03-05
JP2003518922A (ja) 2003-06-17
EP1255824A2 (de) 2002-11-13

Similar Documents

Publication Publication Date Title
Beauquis et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease
Liberski et al. Kuru, the first human prion disease
Finch The biology of human longevity: Inflammation, nutrition, and aging in the evolution of lifespans
Saura et al. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice
Macrì et al. Developmental plasticity of HPA and fear responses in rats: a critical review of the maternal mediation hypothesis
Shoji et al. Age-related changes in behavior in C57BL/6J mice from young adulthood to middle age
Kumar et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease
Miravalle et al. Amino-terminally truncated Aβ peptide species are the main component of cotton wool plaques
Mishra et al. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract
ATE463567T1 (de) Transgene mäuse zur studierung von neurodegenerativen syndromen
Tremml et al. Neurobehavioral development, adult openfield exploration and swimming navigation learning in mice with a modified β-amyloid precursor protein gene
Suo et al. GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment
Guo et al. Modeling Alzheimer’s disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau
Krohn et al. Accumulation of murine amyloid-β mimics early Alzheimer’s disease
EP3907239A4 (de) Monoklonale antikörper gegen die beta-ketten-region von humanem trbv9
Benbow et al. Synergistic toxicity between tau and amyloid drives neuronal dysfunction and neurodegeneration in transgenic C. elegans
Liberski Kuru: a journey back in time from Papua New Guinea to the Neanderthals’ extinction
Alfieri et al. Early cognitive/social deficits and late motor phenotype in conditional wild-type TDP-43 transgenic mice
Oh et al. Natural versus laboratory world: incorporating wild-derived microbiota into preclinical rodent models
Marwarha et al. Retracted: Palmitate‐induced C/EBP homologous protein activation leads to NF‐κB‐mediated increase in BACE1 activity and amyloid beta genesis
Rangasamy et al. Treadmill workout activates PPARα in the hippocampus to upregulate ADAM10, decrease plaques and improve cognitive functions in 5XFAD mouse model of Alzheimer’s disease
US20040031066A9 (en) Mouse model for rheumatoid arthritis
Jiang et al. Impaired plasticity of intrinsic excitability in the dentate gyrus alters spike transfer in a mouse model of Alzheimer's disease
ATE520033T1 (de) Neurotoxische aminosäure oder neurotoxisches derivat davon in zusammenhang mit neurologischen erkrankungen
Sakatani et al. Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1255824

Country of ref document: EP